The special meeting vote is the defining catalyst — monitor preliminary proxy clearing and shareholder approval timing. A failed vote would force alternative restructuring or delisting. If approved, the combined entity's value hinges on Zcash price and Fortitude's mining execution; watch ZEC/USD and hashprice trends for post-merger read-through.
Price Chart
Executive Summary
HeartSciences filed a preliminary proxy statement and DEFA14A soliciting shareholder approval for its all-stock merger with Fortitude Mining Holdings, a Zcash mining operator. The company reported no meaningful revenue and just $1.7M in cash for fiscal 2026, highlighting a distressed position that makes deal approval critical for survival. Pro forma combined equity is $70M, but current shareholders face massive dilution and a potential 1:5 reverse split to maintain Nasdaq listing.
Key Financial Metrics
Key Facts
- No meaningful revenue for fiscal 2026; cash of ~$1.7M and shareholders' equity of ~$0.2M.
- Preliminary proxy filed for all-stock merger with Fortitude Mining Holdings, including issuance of ~107.6M new Class V Common shares to Digital Currency Group.
- Pro forma combined shareholders' equity shown as $70.0M.
- Proposal to authorize a 1-for-2 to 1-for-5 reverse stock split if needed for Nasdaq listing.
- Fortitude mined 72,696 ZEC in six months (~28% of network; estimates >$50M run-rate Adjusted EBITDA at Zcash above $500).
- MyoVista Insights platform commercially launched and MyoVista wavECG device under FDA 510(k) review.
Financial Impact
Zero-revenue pre-merger entity with $1.7M cash and $0.2M equity merging via all-stock deal; pro forma equity $70M. Dilution to current shareholders is extreme (~107.6M new shares to DCG).
Risk Factors
- Merger fails to gain shareholder approval, leaving HeartSciences without a viable path forward.
- Dilution from 107.6M share issuance to DCG severely reduces current HSCS ownership.
- Reverse stock split may depress sentiment and does not fix underlying business economics.
- Zcash price volatility directly impacts Fortitude's projected $50M+ EBITDA and combined company valuation.
- Nasdaq listing not guaranteed post-merger; reverse split may not cure deficiency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-082579 |
| Document: ea0299627-8k_heart.htm | 0001213900-26-082579 |
| Document: 0001213900-26-082579-index-headers.html | 0001213900-26-082579 |
| Document: 0001213900-26-082579-index.html | 0001213900-26-082579 |
| Document: 0001213900-26-082579.txt | 0001213900-26-082579 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | — | awaiting T+1 | — | — |
Oct 26, 2026 today | DEFA14A | — | awaiting T+1 | — | — |
Oct 23, 2026 2d ago | SC 13D/A | $3.41 | awaiting T+1 | — | $3.18 (−6.74%) |
Oct 21, 2026 5d ago | DEFA14A | $3.17 $3.14 | ▼ −0.95% | ▼ −0.42% | $3.18 (+0.32%) |
Oct 19, 2026 7d ago | DEFA14A | $3.13 $3.56 | ▲ +13.74% | ▲ +13.21% | $3.18 (+1.60%) |
Oct 19, 2026 7d ago | DEFA14A | $3.07 $3.13 | ▲ +1.95% | ▲ +1.62% | $3.18 (+3.58%) |
Oct 19, 2026 7d ago | DEFM14A | $3.07 $3.13 | ▼ −1.95% | ▼ −1.62% | $3.18 (−3.58%) |
Oct 15, 2026 11d ago | DEFA14A | $3.02 $3.07 | ▲ +1.66% | ▲ +1.23% | $3.18 (+5.30%) |
Oct 9, 2026 17d ago | 424B5 | $3.30 $3.09 | ▲ +6.36% | ▲ +6.35% | $3.18 (+3.64%) |
Oct 6, 2026 20d ago | DEFA14A | $3.49 $3.04 | ▼ −12.89% | ▼ −12.47% | $3.18 (−8.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers